Drug Sponsors

Meda acquires Acton Pharmaceuticals

Friday, August 30, 2013 02:27 PM

Meda, an international specialty pharmaceutical company, has acquired Acton Pharmaceuticals for $135 million, plus a milestone payment of $10 million and royalties. The acquisition is expected to close during the fourth quarter and is subject to customary closing conditions and U.S. regulatory approval. Existing credit facilities will fund the acquisition.

More... »

Humana, Lilly collaborate to improve healthcare outcomes

Friday, August 30, 2013 02:24 PM

Humana, a Louisville, Ky.-based health and well-being company, and Eli Lilly have signed a multi-year collaboration to improve the healthcare of their members and patients.

More... »

OPKO acquires Prolor Biotech

Friday, August 30, 2013 02:19 PM

OPKO Health, a multinational biopharmaceutical and diagnostics company, has acquired Prolor Biotech, a clinical-stage biopharmaceutical company. Stockholders of Prolor will receive 0.9951 shares of OPKO common stock for each share of Prolor common stock. The stockholders of both companies approved all proposals presented at their respective stockholder meetings.

More... »

Akorn to acquire Hi-Tech Pharmacal

Wednesday, August 28, 2013 12:40 PM

Akorn, a niche pharmaceutical company developing, manufacturing and marketing multisource and branded pharmaceuticals with a focus on sterile ophthalmic and injectables, will acquire Hi-Tech Pharmacal, a specialty pharmaceutical company developing, manufacturing and marketing generic and branded prescription and over-the-counter (OTC) products,  for $640 million in cash.

More... »

Sangamo BioSciences to acquire Ceregene

Wednesday, August 28, 2013 12:35 PM

Sangamo BioSciences has agreed to acquire Ceregene, a privately held biotechnology company focused on developing adeno-associated virus (AAV) gene therapies. 

More... »

Imprimis acquires intellectual property from Novel Drug Solutions, Eye Care Northwest

Wednesday, August 28, 2013 12:32 PM

Imprimis Pharmaceuticals, focused on the commercialization of drug formulations through a growing proprietary network of compounding pharmacy relationships, has acquired intellectual property from Novel Drug Solutions and Eye Care Northwest, including a provisional patent application related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents. Imprimis believes this formulation could affect the $5 billion global cataract surgery drug market. The acquisition allows Imprimis to pursue the commercial development of certain proprietary innovations and also provides Imprimis with a preemptive right on additional intellectual property and drug development opportunities.

More... »

Chiesi Group to acquire Zymenex

Tuesday, August 27, 2013 10:30 AM

Chiesi Group, a European pharmaceutical company, has agreed to acquire Danish biopharmaceutical company Zymenex and its related group of companies, a biopharmaceutical group focused on R&D of biologic therapeutics for the treatment of rare and life threatening genetic diseases. Terms of the transaction were not disclosed.

More... »

MedImmune acquires Amplimmune

Monday, August 26, 2013 12:24 PM

AstraZeneca has announced that MedImmune, its global biologics R&D arm, has agreed to acquire Amplimmune, a privately-held, Maryland-based biologics company focused on developing novel therapeutics in cancer immunology.

More... »

Immune Pharmaceuticals, EpiCept complete merger

Monday, August 26, 2013 12:15 PM

Immune Pharmaceuticals has completed its merger with EpiCept. The merger combines Immune's antibody therapeutic platform focused on the treatment of inflammatory diseases and cancer with EpiCept's early-stage cancer program and its late-stage topical pain product, AmiKet.

More... »

Amgen to acquire Onyx Pharmaceuticals

Monday, August 26, 2013 12:07 PM

Amgen will acquire San Francisco, Calif.-based Onyx Pharmaceuticals, purchasing all of the outstanding shares of Onyx for $125 per share in cash, for a total purchase price of $10.4 billion, or $9.7 billion net of estimated Onyx cash. The boards of both companies have approved the transaction.

More... »